title: Imatinib-induced immune hepatitis: case report and literature review.
abstract: Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML. Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported. Only a few cases so far have been reported in the literature and almost all were in females. We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes. The case described here suggests that imatinib may also induce immune hepatitis, in some patients.
authors: Department of Pathology and Laboratory Medicine, King Khalid National Guard Hospital, Jeddah, Saudi Arabia. ensobhi@hotmail.com
authors: Enaam
authors: E
authors: Al Sobhi
authors: Zayed
authors: Z
authors: Zahrani
authors: Eduardo
authors: E
authors: Zevallos
authors: Abdo
authors: A
authors: Zuraiki
mesh_terms: D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D000974:Antibodies, Antinuclear / Q000097:blood; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001323:Autoantibodies / Q000097:blood; D001324:Autoantigens / Q000276:immunology; D001549:Benzamides; D004247:DNA / Q000276:immunology; D005260:Female; D019693:Hepatitis, Autoimmune / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D041781:Jaundice, Obstructive / Q000139:chemically induced; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000188:drug therapy; D009130:Muscle, Smooth / Q000276:immunology; D010879:Piperazines / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000974:Antibodies, Antinuclear; D000970:Antineoplastic Agents; D001323:Autoantibodies; D001324:Autoantigens; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D004247:DNA; D011239:Prednisolone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase